MedTrace Logo

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

NCT03981705 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2024-12-27

No results posted yet for this study

Summary

This is a feasibility study to gain preliminary information regarding whether breast imaging with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery can accurately predict complete pathologic response (pCR) in women with triple negative or HER2- positive breast cancer. pCR is defined as having no residual invasive breast cancer or ductal carcinoma in situ.

Conditions

Interventions

RADIATION

Standard Trimodality Breast Imaging

Standard breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC).

Sponsors & Collaborators

  • Masonic Cancer Center, University of Minnesota

    lead OTHER

Principal Investigators

  • Todd Tuttle, MD, MS · Department of Surgery, University of Minnesota

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-08
Primary Completion
2024-02-19
Completion
2024-11-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03981705 on ClinicalTrials.gov